Biosion

Privately held: no public share price

Assets

(2 total)
2Total Assets
0Approved
0Phase 3 / Filed
2Phase 1–2 / Early
1Diseases
Showing 2 of 2 assets
Target & Modality
Phase 2
TSLPMonoclonal antibody
Atopic Dermatitis
Preclinical / Unstaged
IL-4Rα and TSLPMultispecific antibody
Atopic Dermatitis

Upcoming events

No upcoming trial completions or earnings dates on record for this company's assets.

Regulatory and conference events

(2)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

16 November 2026Topline resultBosakitugPhase 2 ADMIRATION trial of bosakitug misses primary endpoint
27 October 2026Topline resultATI-052Phase 1b POC primary analysis in atopic dermatitis

Financial reports

No financial reports recorded.